Capsule inhaler ICOcap™ from Iconovo CE-marked for clinical trials
Iconovo announce that the capsule-based dry powder inhaler ICOcap™ is CE-marked for use in clinical trials
ICOcap™ is now available for customers to use in clinical trials that develop capsule-based formulations and can be bought from Stevanato, the manufacturing and distribution partner of Iconovo. The CE mark is applied in conformity with the requirements of Directive 93/42/EEC as a Class 1 Medical Device in collaboration with our partners Stevanato Group and their affiliate Balda Medical GmbH.